NCT07159217 2025-09-08
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
Clinical Trials
13 trialsNCT05586061 2025-02-07
RCTS
Qilu Hospital of Shandong University
Phase 2 Active not recruiting
NCT06730373 2024-12-31
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT06650332 2024-10-21
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Zhejiang Cancer Hospital
Phase 1/2 Recruiting
NCT06560528 2024-08-19
Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06492317 2024-07-09
RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT06385873 2024-05-13
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06233864 2024-04-17
A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT05578287 2023-12-07
DETECT
Sun Yat-sen University
Phase 2 Unknown
NCT06078982 2023-10-12
Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer
Shanghai East Hospital
Phase 1 Unknown
NCT05627414 2022-11-25
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05493683 2022-10-21
Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05333809 2022-04-20
Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown